Fox Chase Cancer Center, Philadelphia, PA
Arthur Winer , Elizabeth A. Handorf , Lavanya Nagappan , Aryeh Blumenreich , Farhana Chowdhury , Namrata Vijayvergia , Efrat Dotan
Background: The median age at diagnosis for metastatic pancreatic cancer (mPC) is 72. Gemcitabine and Nab-Paclitaxel (GA) is often the preferred chemo regimen in this population due to presumed reduced toxicity compared with FOLFIRINOX. While the traditional GA schedule (TDS) includes treatment on days 1, 8, and 15 of a 28-day cycle, it can cause side effects and patients often require dose reductions. There is data for a modified dosing schedule (MDS) treating only on day 1 and 15. Therefore, we retrospectively analyzed our older adults treated with GA using the TDS versus the MDS and compared tolerability and outcomes between the two groups. Methods: We identified pts with mPC >64 y/o treated with GA at Fox Chase Cancer Center between 1/2010 - 7/2018 and collected their demographic, disease and treatment information. We analyzed discrete variables using Fisher’s exact test and continuous variables using Wilcoxon tests. Overall survival (OS) was analyzed by the Kaplan-Meier method and Cox proportional hazards regression. Results: Fifty-six pts were identified with a median age at diagnosis of 71 (range: 64-90) and 67.8% with metastatic disease at presentation. 57% received GA in the first line. 44% were treated with TDS while 56% received a MDS; an older median age was seen in the MDS group (73 vs 69 y/o, p<0.001). Up front dose reductions of GA were seen in 24% in the TDS vs 48% in MDS, and they were more common with nab-paclitaxel (26% in MDS vs 10% in TDS) than with gemcitabine (two pts in TDS vs one pt in MDS). Of pts who began with TDS only 11 (19% of all pts) were able to tolerate it without adjustment throughout treatment; 14 (25%) transitioned to the MDS. More pts suffered grade ≥3 toxicity with the TDS vs. MDS (68% vs. 51%; p=0.27) and more required a dose reduction (TDS 72% vs. MDS 48%; p=0.1). 58% required an additional GA dose reduction over the course of treatment. Median OS among GA treated pts in the front line (n=32) was not significantly different (MDS: 11.7 mo vs. TDS: 13 mo; p=0.1). Conclusions: These results demonstrate tolerability and similar efficacy of the GA MDS among older adults with mPC. Given the limited sample size, further studies are required to help establish the appropriate therapy for older patients.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kazuki Watabe
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kenji Ikezawa
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Yan-Shen Shan
2023 ASCO Annual Meeting
First Author: Benedikt Westphalen